haloperidol has been researched along with Insulin Sensitivity in 9 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Excerpt | Relevance | Reference |
---|---|---|
"The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 7.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
"The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 3.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
" To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis." | 3.73 | Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006) |
"Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels." | 2.74 | Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. ( Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2009) |
"Haloperidol treatment reduced the voluntary activity and energy expenditure of DR mice and induced insulin resistance in these mice." | 1.37 | Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice. ( de Leeuw van Weenen, JE; Parlevliet, ET; Pijl, H; Romijn, JA; Schröder-van der Elst, JP; van den Berg, SA; Willems van Dijk, K, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 7 (77.78) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Calevro, A | 1 |
Cotel, MC | 1 |
Natesan, S | 1 |
Modo, M | 1 |
Vernon, AC | 1 |
Mondelli, V | 1 |
Melkersson, K | 1 |
Lewitt, M | 1 |
Hall, K | 1 |
Perez-Iglesias, R | 1 |
Mata, I | 1 |
Pelayo-Teran, JM | 1 |
Amado, JA | 1 |
Garcia-Unzueta, MT | 1 |
Berja, A | 1 |
Martinez-Garcia, O | 1 |
Vazquez-Barquero, JL | 1 |
Crespo-Facorro, B | 1 |
Boyda, HN | 1 |
Tse, L | 1 |
Procyshyn, RM | 1 |
Wong, D | 1 |
Wu, TK | 1 |
Pang, CC | 1 |
Barr, AM | 1 |
Albaugh, VL | 1 |
Vary, TC | 1 |
Ilkayeva, O | 1 |
Wenner, BR | 1 |
Maresca, KP | 1 |
Joyal, JL | 1 |
Breazeale, S | 1 |
Elich, TD | 1 |
Lang, CH | 1 |
Lynch, CJ | 1 |
Victoriano, M | 1 |
de Beaurepaire, R | 1 |
Naour, N | 1 |
Guerre-Millo, M | 1 |
Quignard-Boulangé, A | 1 |
Huneau, JF | 1 |
Mathé, V | 1 |
Tomé, D | 1 |
Hermier, D | 1 |
de Leeuw van Weenen, JE | 2 |
Auvinen, HE | 1 |
Parlevliet, ET | 2 |
Coomans, CP | 1 |
Schröder-van der Elst, JP | 2 |
Meijer, OC | 1 |
Pijl, H | 2 |
van den Berg, SA | 1 |
Willems van Dijk, K | 1 |
Romijn, JA | 1 |
Lin, EJ | 1 |
Lee, NJ | 1 |
Slack, K | 1 |
Karl, T | 1 |
Duffy, L | 1 |
O'brien, E | 1 |
Matsumoto, I | 1 |
Dedova, I | 1 |
Herzog, H | 1 |
Sainsbury, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers[NCT00741026] | 15 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
BMI (NCT00741026)
Timeframe: 3 Days
Intervention | kg / m2 (Mean) |
---|---|
Placebo | 23.0 |
Olanzapine | 23.0 |
Body Weight (NCT00741026)
Timeframe: 3 Days
Intervention | kg (Mean) |
---|---|
Placebo | 68.2 |
Olanzapine | 68.9 |
Diastolic Blood Pressure (NCT00741026)
Timeframe: 3 Days
Intervention | mmHg (Mean) |
---|---|
Placebo | 68.3 |
Olanzapine | 69.5 |
HDL Cholesterol (NCT00741026)
Timeframe: 3 Days
Intervention | mg/dl (Mean) |
---|---|
Placebo | 54.2 |
Olanzapine | 48.9 |
Heart Rate (NCT00741026)
Timeframe: 3 Days
Intervention | beats per minute (Mean) |
---|---|
Placebo | 69.9 |
Olanzapine | 67.6 |
LDL Cholesterol (NCT00741026)
Timeframe: 3 Days
Intervention | mg/dl (Mean) |
---|---|
Placebo | 82.7 |
Olanzapine | 81.7 |
Oral Glucose Tolerance (NCT00741026)
Timeframe: 3 Days
Intervention | min*mg/dl (Mean) |
---|---|
Placebo | 2808 |
Olanzapine | 3984 |
Plasma Free Fatty Acid (NCT00741026)
Timeframe: 3 Days
Intervention | mM (Mean) |
---|---|
Placebo | 0.38 |
Olanzapine | 0.26 |
Leptin following placebo or olanzapine treatment (NCT00741026)
Timeframe: 3 Days
Intervention | ng/ml (Mean) |
---|---|
Placebo | 6.8 |
Olanzapine | 8.4 |
Systolic Blood Pressure (NCT00741026)
Timeframe: 3 Days
Intervention | mmHg (Mean) |
---|---|
Placebo | 113.3 |
Olanzapine | 111.7 |
Total Cholesterol (NCT00741026)
Timeframe: 3 Days
Intervention | mg/dl (Mean) |
---|---|
Placebo | 156.8 |
Olanzapine | 152.6 |
Triglycerides (NCT00741026)
Timeframe: 3 Days
Intervention | mg/dl (Mean) |
---|---|
Placebo | 88.9 |
Olanzapine | 108.2 |
1 trial available for haloperidol and Insulin Sensitivity
Article | Year |
---|---|
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Cholesterol, H | 2009 |
8 other studies available for haloperidol and Insulin Sensitivity
Article | Year |
---|---|
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.
Topics: Adipose Tissue; Adiposity; Animals; Antigens, Differentiation; Antipsychotic Agents; Biomarkers; Car | 2018 |
Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics.
Topics: Adult; Amino Acids; Antipsychotic Agents; Chromatography, Ion Exchange; Clopenthixol; Clozapine; Coh | 2015 |
A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Blood Glucose; Clozapine; Dose-Response Relatio | 2010 |
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carnitine; Clozapine; Energy Metabolism; Fatty Acids | 2012 |
Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.
Topics: Adipose Tissue; Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Cytokines; Glu | 2010 |
Blocking dopamine D2 receptors by haloperidol curtails the beneficial impact of calorie restriction on the metabolic phenotype of high-fat diet induced obese mice.
Topics: Animals; Body Weight; Caloric Restriction; Dietary Fats; Dopamine Antagonists; Dopamine D2 Receptor | 2011 |
Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.
Topics: Animals; Behavior, Animal; Body Weight; Bromocriptine; Dietary Fats; Dopamine Agonists; Dopamine Ant | 2011 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli | 2006 |